Bolt Biotherapeutics

Nectin Therapeutics

This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.

Cytospire Therapeutics

This company develops multispecific immune cell engager antibodies for cancer patients to enhance and direct immune system activity against solid tumours.

Hummingbird Bioscience

This company develops antibody-based therapeutics and drug conjugates for patients with hard-to-treat cancers and autoimmune diseases.

Xilio Therapeutics

This biotechnology company develops tumour-activated immuno-oncology therapies designed to treat patients with solid cancers while reducing systemic side effects.

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

Clinical stage immunotherapy company

This company develops next-generation antibody-drug conjugates to treat patients with solid tumor malignancies.

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

Emergence Therapeutics

This biopharmaceutical company develops antibody-drug conjugate immunotherapies to treat solid tumours for patients with high unmet medical needs.